StockNews.AI
CCM
StockNews.AI
4 hrs

Concord Medical Reports Financial Results for the First Half of 2025

1. CCM's net revenues dropped 8.3% to RMB200.6 million in H1 2025. 2. Gross loss improved to RMB4.3 million from RMB41.6 million last year. 3. Net loss decreased significantly to RMB27.1 million compared to RMB172.3 million. 4. Hospital business revenues rose by 11.1% due to proton therapy operations. 5. Network business revenues fell by 41.3% amid decreased demand for equipment.

Earnings
0%Current Return
VS
+0.14%S&P 500
$6.5709/26 07:35 AM EDTEvent Start
$6.5709/26 10:46 AM EDTLatest Updated
30m saved
Insight
Article

FAQ

Why Bullish?

The significant reduction in losses alongside revenue increases from the hospital segment suggests operational improvements. A similar trend in 2022, following cost reductions and new service offerings, positively influenced stock prices.

How important is it?

The article highlights significant operational improvements and strategic focus on growth, which investors tend to view positively. Improved loss margins and new treatment capabilities align with increasing oncology demands.

Why Short Term?

Immediate improvements in financial metrics, especially in the hospital business, may attract investor attention rapidly. Historical patterns show that major earnings updates often lead to short-term stock price movements.

Related Companies

HCAUHSMOH
, /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network business of RMB47.6 million (US$6.6 million). Gross loss was RMB4.3 million (US$0.6 million) in the first half of 2025, compared to the gross loss of RMB41.6 million in the first half of 2024. The gross loss margin was 2.1% for the first half of 2025, compared to 19.0% for the same period last year. Net loss attributable to ordinary shareholders in the first half of 2025 was RMB27.1 million (US$3.8 million), compared to RMB172.3 million in the same period last year. Basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2025 were both RMB0.21 (US$0.03), compared to RMB1.31 in the same period last year. Adjusted EBITDA[2] was negative RMB62.2 million (US$8.7 million) in the first half of 2025, compared to negative RMB148.0 million in the same period last year. [1] This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations of RMB into U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the noon buying rate in New York City for cable transfers payable in RMB, as certified for customs purposes by the Federal Reserve Bank of New York on June 30, 2025. [2] Adjusted EBITDA is defined as net income/(loss) plus interest expenses, net, income tax expenses, depreciation and amortization and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "The precision of proton therapy helps prevent long-term damage to critical functional areas—including the brain, heart, and rectum—while allowing clinicians to safely escalate radiation doses to target sites to improve efficacy in refractory cancers. With minimal impact on surrounding normal tissues, patients benefit from fewer side effects and faster recovery, making proton therapy an optimal treatment option in cases where balancing efficacy and safety is critical. As the first proton therapy center in South mainland China to commence clinical operations, Guangzhou Concord Cancer Hospital has developed specialized treatment protocols for a range of malignancies. In patients with nasopharyngeal carcinoma, aged between 10 and 71, we observed significant tumor regression, with elderly patients experiencing only mild mucosal reactions. For central nervous system tumors, the hospital achieved successful functional preservation even in extensive irradiation fields such as whole-brain and whole-spine treatments. In pediatric care, as of June 30, the Company treated its youngest proton therapy patient, a child of just over one year old. Through advanced radiotherapy techniques and careful anesthetic management, the hospital was able to provide effective protection and treatment. These results highlight the clinical value of proton therapy in improving outcomes for challenging cancers while preserving function in critical organs. Looking forward, the Company will remain committed to advancing proton therapy, enhancing public understanding of precision radiotherapy, strengthening patient confidence, and expanding patient access to internationally advanced diagnostic and therapeutic technologies, innovative medications, and patient-centered care." 2025 First Half Financial Results Net Revenues Hospital Business Net revenues from the hospital business were RMB153.0 million (US$21.4 million) in the first half of 2025, representing a 11.1% increase from net revenues of RMB137.8 million in the first half of 2024, mainly because of the commencement of proton therapy operations at Guangzhou Concord Cancer Hospital. Network Business Net revenues from the network business were RMB47.6 million (US$6.6 million), representing a 41.3% decrease from net revenues of RMB81.0 million in the first half of 2024, mainly because (1) demand for medical equipment and software decreased under the current macroeconomic environment, leading to delayed overall business demand, and (2) operating lease revenue decreased since this is no longer the Company's main business and expired contracts were not renewed. Cost of Revenues Hospital Business Cost of revenues of the hospital business in the first half of 2025 was RMB157.2 million (US$21.9 million), representing a 9.6% decrease from cost of revenues of RMB174.0 million in the first half of 2024, mainly because (1) efficiency of human resources improved as the Company implemented a strategy focused on enhancing operational efficiency and reducing costs, (2) consumables cost, maintenance cost and lease cost decreased along with the development of the hospital business. Network Business Cost of revenues of the network business was RMB47.7million (US$6.7 million), representing a 44.8% decrease from RMB86.4 million in the first half of 2024, mainly because of the decrease in cost as a result of the decrease in revenue generated from sales and installation of medical equipment and software, and from management and technical support services. Gross Loss and Gross Loss Margin Gross loss from the operating business was RMB4.3million (US$0.6 million) in the first half of 2025, compared to RMB41.6 million in the same period last year. The gross loss margin for the first half of 2025 was 2.1%, compared to the gross loss margin of 19.0% for the same period last year. The improvement in gross loss margin of the operating business was mainly because of adjustments in the Company's revenue structure, with the commencement of the proton therapy business bringing efficiency improvements, and the strategic focus on enhancing operational efficiency and reducing costs. Operating Expenses Selling expenses were RMB21.0 million (US$2.9 million) in the first half of 2025, compared to RMB25.0 million in the first half of 2024. Selling expenses as a percentage of net revenues was 10.5% in the first half of 2025, compared to 11.4% in the first half of 2024. General and administrative expenses were RMB119.4 million (US$16.7 million) in the first half of 2025, of which employee benefit expenses were RMB51.0 million (US$7.1 million). In the same period of last year, general and administrative expenses were RMB131.2 million. The decrease was mainly attributable to the decrease in staff cost and listing expenses, and the strategic focus on enhancing operational efficiency and reducing costs. General and administrative expenses as a percentage of net revenues were 59.5% in the first half of 2025, compared to 59.9% in the first half of 2024. Capital Expenditures Comparing to RMB168.4 million in the first half of 2024, capital expenditures were RMB100.6 million (US$14.0 million) in the first half of 2025, mainly due to the decrease in deposit for equipment and construction fees for our hospital business. Bank Loans and Other Borrowings As of June 30, 2025, the Company had bank loans and other borrowings totaling RMB3.6 billion (US$508.4 million). About Non-GAAP Financial Measures To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), Concord Medical uses certain non-GAAP measures. Concord Medical presents the non-GAAP measure of adjusted EBITDA, which is defined in this announcement as net loss plus interest expenses, net, income tax expenses, depreciation and amortization and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. Furthermore, adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information. About Concord Medical Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.  Safe Harbor Statement This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Concord Medical Services Holdings Co., Ltd. Consolidated Balance Sheets (in thousands) December 31, 2024 June 30, 2025 RMB RMB US$ (Audited) (Unaudited) (Unaudited) ASSETS Current assets Cash and cash equivalents 216,224 177,389 24,763 Short-term investment 134,621 - - Restricted cash, current portion 20,758 20,216 2,822 Accounts receivable, net 51,168 57,360 8,007 Prepayments and other current assets, net 527,760 756,672 105,627 Inventories 33,441 13,691 1,911 Total current assets 983,972 1,025,328 143,130 Non-current assets Property, plant and equipment, net 3,704,325 3,684,147 514,287 Right-of-use assets, net 520,817 507,849 70,893 Goodwill 572,216 572,216 79,878 Intangible assets, net 292,142 273,976 38,246 Deposits for non-current assets 174,883 210,055 29,323 Long-term investments 472,166 457,016 63,797 Other non-current assets 5,867 2,878 402 Total non-current assets 5,742,416 5,708,137 796,826 Total assets 6,726,388 6,733,465 939,956 LIABILITIES AND EQUITY Current liabilities Accounts payable 199,394 112,190 15,661 Accrued expenses and other liabilities 846,194 904,149 126,214 Income tax payable 1,623 16,416 2,292 Operating lease liabilities, current 45,448 47,061 6,569 Short-term bank and other borrowings 649,680 611,708 85,391 Long-term bank and other borrowings, current portion 383,016 762,772 106,479 Total current liabilities 2,125,355 2,454,296 342,606 Non-current liabilities Long-term bank and other borrowings, non-current portion 2,693,693 2,267,655 316,554 Deferred tax liabilities 82,870 80,134 11,186 Operating lease liabilities, non-current 138,894 133,332 18,612 Other long-term liabilities 67,827 76,028 10,613 Total non-current liabilities 2,983,284 2,557,149 356,965 Total liabilities 5,108,639 5,011,445 699,571 EQUITY Class A ordinary shares 68 68 10 Class B ordinary shares 37 37 5 Treasury stock (7) (7) (1) Additional paid-in capital 2,169,693 2,230,839 311,413 Accumulated other comprehensive loss (77,349) (70,404) (9,828) Accumulated deficit (4,372,832) (4,399,967) (614,212) Total Concord Medical Services Holdings Limited shareholders' deficit (2,280,390) (2,239,434) (312,613) Noncontrolling interests 3,898,139 3,961,454 552,998 Total equity 1,617,749 1,722,020 240,385 Total liabilities and equity 6,726,388 6,733,465 939,956 Concord Medical Services Holdings Co., Ltd. Consolidated Profit & Loss (in thousands, except for number of shares and per share data) June 30, 2024 June 30, 2025 RMB RMB US$ (Unaudited) (Unaudited) (Unaudited) Revenues, net of business tax, value-added tax and related surcharges Hospital 137,772 153,007 21,359 Network 81,038 47,608 6,646 Total net revenues 218,810 200,615 28,005 Cost of revenues: Hospital (173,963) (157,192) (21,943) Network (86,443) (47,706) (6,660) Total cost of revenues (260,406) (204,898) (28,603) Gross loss (41,596) (4,283) (598) Operating expenses: Selling expenses (24,975) (21,006) (2,932) General and administrative expenses (131,173) (119,361) (16,662) Operating loss (197,744) (144,650) (20,192) Interest expense (68,668) (87,660) (12,237) Foreign exchange loss, net (30,269) (1,906) (266) Interest income 5,990 4,574 639 Change in fair value of derivative liability (108,777) - - Income from equity method investments 6,070 7,477 1,044 Gain on disposal of subsidiaries 47,997 - - Other expenses, net 1,388 (894) (125) Gain on disposal of equity method investment - 37,471 5,231 Changes in fair value of short-term investments 6,631 - - Loss before income tax (337,382) (185,588) (25,906) Income tax expenses 8,674 (19,784) (2,762) Net loss (328,708) (205,372) (28,668) Net loss attributable to noncontrolling interests (156,450) (178,237) (24,881) Net loss attributable to Concord Medical Services Holdings Limited (172,258) (27,135) (3,787) Loss per share for Class A and Class B ordinary shares Basic (1.31) (0.21) (0.03) Diluted (1.31) (0.21) (0.03) Weighted average number of class A and class B ordinary shares outstanding: Basic 131,053,858 131,053,858 131,053,858 Diluted 131,053,858 131,053,858 131,053,858 Other comprehensive loss, net of tax of nil Foreign currency translation, net tax of nil (6,273) 6,945 969 Total other comprehensive loss, net of tax (6,273) 6,945 969 Comprehensive loss (334,981) (198,427) (27,699) Comprehensive loss attributable to noncontrolling interests (156,450) (178,237) (24,881) Comprehensive loss attributable to Concord Medical Services Holdings Limited's shareholders (178,531) (20,190) (2,818) Reconciliation from net income to adjusted EBITDA(*) (in RMB thousands, unaudited) For the six months ended For the six months ended June 30, 2024 June 30, 2025 Net loss (328,708) (205,372) Interest expenses, net 62,678 83,086 Income tax expenses (8,674) 19,784 Depreciation and amortization 43,654 74,985 Other adjustments 83,030 (34,671) Adjusted EBITDA (148,020) (62,188) EBITDA margin -68 % -31 % (*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net loss plus interest expenses, net, income taxexpenses, depreciation and amortization, and other adjustments. Other adjustments include foreign exchange loss, net,other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair valueof derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. SOURCE Concord Medical Services Holdings Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News